Ineligibility for Anticoagulation in Patients with Atrial Fibrillation

被引：9

作者：

del Conde, Ian ^{[1
]}

Halperin, Jonathan L. ^{[1
]}

机构：

[1] Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA

来源：

AMERICAN JOURNAL OF MEDICINE | 2013年 / 126卷 / 02期

关键词：

Anticoagulation; Atrial fibrillation; Bleeding; Eligibility; Stroke; CLINICAL CLASSIFICATION SCHEMES; BLEEDING RISK; ANTITHROMBOTIC THERAPY; NATIONAL REGISTRY; ELDERLY-PATIENTS; WARFARIN; STROKE; HEMORRHAGE; DABIGATRAN; PREDICTION;

D O I：

10.1016/j.amjmed.2012.07.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although anticoagulation therapy markedly reduces the risk of stroke in patients with atrial fibrillation, up to 50% of these patients are deemed ineligible for anticoagulation. In this manuscript we provide a framework to assess the net clinical benefit of anticoagulation in patients with atrial fibrillation with an increased risk of bleeding. We also review recent data related to the novel oral anticoagulants targeting thrombin or factor Xa, and discuss how the introduction of these agents raises the distinction between eligibility for vitamin K antagonist therapy specifically, and eligibility for anticoagulation in general. (C) 2013 Elsevier Inc. All rights reserved. The American Journal of Medicine (2013) 126, 105-111

引用

页码：105 / 111

页数：7

共 35 条

[1] Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran [J].

Beasley, B. Nhi ;

Unger, Ellis F. ;

Temple, Robert .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1788-1790

[2]

Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/europace/euq350, 10.1093/eurheartj/ehq278]

[3]

Chesebro JH, 1996, ARCH INTERN MED, V156, P409

[4] Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation [J].

Connolly, S. J. ;

Yusuf, S. ;

Camm, J. ;

Chrolavicius, S. ;

Commerford, P. ;

Flather, M. ;

Hart, R. G. ;

Hohnloser, S. H. ;

Joyner, C. ;

Pfeffer, M. ;

Gaudin, C. ;

Blumenthal, M. ;

Marchese, C. ;

Pogue, J. ;

Hart, R. ;

Hohnloser, S. ;

Anand, I. ;

Arthur, H. ;

Avezum, A. ;

Budaj, A. ;

Ceremuzynski, L. ;

De Caterina, R. ;

Diaz, R. ;

Dorian, P. ;

Flaker, G. ;

Fox, K. A. A. ;

Franzosi, M. G. ;

Goldhaber, S. ;

Golitsyn, S. ;

Granger, C. ;

Halon, D. ;

Hermosillo, A. ;

Hunt, D. ;

Jansky, P. ;

Karatzas, N. ;

Keltai, M. ;

Kozan, O. ;

Lanas, F. ;

Lau, P. ;

Le Heuzey, J. Y. ;

Lewis, B. S. ;

Morais, J. ;

Morillo, C. ;

Paolasso, E. ;

Peters, R. J. ;

Pfisterer, M. ;

Piegas, L. ;

Pipilis, A. ;

Sitkei, E. ;

Swedberg, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20) :2066-2078

[5] Apixaban in Patients with Atrial Fibrillation [J].

Connolly, Stuart J. ;

Eikelboom, John ;

Joyner, Campbell ;

Diener, Hans-Christoph ;

Hart, Robert ;

Golitsyn, Sergey ;

Flaker, Greg ;

Avezum, Alvaro ;

Hohnloser, Stefan H. ;

Diaz, Rafael ;

Talajic, Mario ;

Zhu, Jun ;

Pais, Prem ;

Budaj, Andrzej ;

Parkhomenko, Alexander ;

Jansky, Petr ;

Commerford, Patrick ;

Tan, Ru San ;

Sim, Kui-Hian ;

Lewis, Basil S. ;

Van Mieghem, Walter ;

Lip, Gregory Y. H. ;

Kim, Jae Hyung ;

Lanas-Zanetti, Fernando ;

Gonzalez-Hermosillo, Antonio ;

Dans, Antonio L. ;

Munawar, Muhammad ;

O'Donnell, Martin ;

Lawrence, John ;

Lewis, Gayle ;

Afzal, Rizwan ;

Yusuf, Salim .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (09) :806-817

[6] Newly Identified Events in the RE-LY Trial [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Reilly, Paul A. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19) :1875-1876

[7] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[8] Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects [J].

Eerenberg, Elise S. ;

Kamphuisen, Pieter W. ;

Sijpkens, Meertien K. ;

Meijers, Joost C. ;

Buller, Harry R. ;

Levi, Marcel .

CIRCULATION, 2011, 124 (14) :1573-1579

[9] A New Risk Scheme to Predict Warfarin-Associated Hemorrhage The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study [J].

Fang, Margaret C. ;

Go, Alan S. ;

Chang, Yuchiao ;

Borowsky, Leila H. ;

Pomernacki, Niela K. ;

Udaltsova, Natalia ;

Singer, Daniel E. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (04) :395-401

[10] Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation [J].

Fang, MC ;

Chang, YC ;

Hylek, EM ;

Rosand, J ;

Greenberg, SM ;

Go, AS ;

Singer, DE .

ANNALS OF INTERNAL MEDICINE, 2004, 141 (10) :745-752

← 1 2 3 4 →